RecruitingNANCT07552584

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

Sponsor: Vejle Hospital

Trial Details

Condition	Lung Cancer (Diagnosis)
Intervention	Risk stratification
Phase	NA
Status	Recruiting
Participants	1,000
Est. Completion	1 Apr 2028
Last Updated	6 May 2026

Primary Outcome

Recruitment fraction

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Diagnosed with COPD. * =\> 50 years. * Former or current smoker. * Speaks and understands Danish. * Able to give informed consent to participation. Exclusion Criteria: * Had a CT scan of the thorax within 6 months. * Received active treatment for cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri). * Diagnosed with cancer within one year (except non-melanoma skin cancer and carcinoma in situ cervicis uteri). * Presents with symptoms giving suspicion of cancer (except non-melanoma skin cancer and carcinoma in situ cervicis uteri). * In a condition not allowing diagnostic workup for or treatment of lung cancer. * Does not have Eboks (electronic communication with Danish authorities).

Trial Sites

Countries

Denmark

View Registry Entry

Related Analysis

Danish Feasibility Study Tests Blood-Based AI Risk Stratification for Lung Cancer Detection in COPD Patients — Primary Care Implementation Focus

Danish researchers are testing whether blood-based biomarkers and machine learning can improve lung cancer detection in COPD patients through primary care settings. This feasibility study could transform screening approaches by enabling more precise risk stratification while reducing unnecessary radiation exposure.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service